Theracare Maximum Strength Pain Relief Patch
FDA Recall NDC 71101-001

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Theracare Maximum Strength Pain Relief Patch (NDC 71101-001). A significant event, classified as Class II, was initiated on Oct 24, 2024 by Veridian Healthcare. The reported reason for this action was: "cGMP Deviations"

This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.

Reported Recall Events

October 2024 Class II Recall: cGMP Deviations

Recall Number
Class II Terminated
Reason for Recall
cGMP Deviations
Initiated
Oct 24, 2024
Reported
Dec 04, 2024
Quantity
455,536 patches

Recall Profile & Regulatory Data

Event ID
95595
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
Unexo Life Sciences Private Limited
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the US
Termination Date
Sep 16, 2025
Product Description
THERACARE MAXIMUM STRENGTH PAIN RELIEF 4% LIDOCAINE PATCH, a) 1 patch (NDC 71101-001-24, UPC 8 45717 00878 5) and b) 6 patches (NDC 71101-001-06, UPC 8 45717 01056 6), Manufactured for: Veridian Healthcare, LLC, Gurnee, IL 60031
Batch or Lot Expiration Information
Lot# a) UPC 8 45717 00878 5 b) UPC 8 45717 01056 6
Affected Packages Involved in this Recall
71101-001-06Product
71101-001-24Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.